Milan, Italy (April 19, 2024)

Today, MgShell, a MedTech company that aspires to inspire a change in ophthalmology by developing a magnesium-based drug delivery platform capable of reshaping patient care and enhancing treatment adherence for patients suffering from retinal diseases, announced its winning of the “IDEA” Innovation Dream Engineering Award promoted by Ordine degli Ingegneri di Milano.

The 5th edition of the Concorso IDEA, organized by the Ordine degli Ingegneri di Milano, was the stage for an extraordinary exhibition of innovation in the Italian healthcare sector.

About MgShell:

MgShell, headquartered in Milan, Italy, is a preclinical-stage drug delivery company focused on developing a magnesium-based drug delivery platform capable of reshaping patient care, enhancing treatment adherence for patients suffering from retinal diseases, and lowering healthcare expenses.